云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准公司近期战略增持I-Mab股权

智通财经2025-08-04

云顶新耀(01952)午后涨超8%，截至发稿，涨8.05%，报67.1港元，成交额4.08亿港元。消息面上，据澎湃报道，近期，有患者在社交平台上发帖称，其使用的布地奈德肠溶胶囊(商品名：耐赋康)出现缺货情况。对于缺货情况，云顶新耀表示，公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日，云顶新耀宣布，其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556808239?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-04 13:52","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2556808239","market":"hk","top_or_hot":-1,"title":"云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权","media":"智通财经","content":"<div>\n<p>云顶新耀(01952)午后涨超8%，截至发稿，涨8.05%，报67.1港元，成交额4.08亿港元。消息面上，据澎湃报道，近期，有患者在社交平台上发帖称，其使用的布地奈德肠溶胶囊(商品名：耐赋康)出现缺货情况。对于缺货情况，云顶新耀表示，公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日，云顶新耀宣布，其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080414090094ce0a02&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-04 13:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080414090094ce0a02&s=b><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>云顶新耀(01952)午后涨超8%，截至发稿，涨8.05%，报67.1港元，成交额4.08亿港元。消息面上，据澎湃报道，近期，有患者在社交平台上发帖称，其使用的布地奈德肠溶胶囊(商品名：耐赋康)出现缺货情况。对于缺货情况，云顶新耀表示，公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日，云顶新耀宣布，其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080414090094ce0a02&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080414090094ce0a02&s=b","article_id":"2556808239","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080414090094ce0a02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2556808239","pubTimestamp":1754286726,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"对于缺货情况，云顶新耀表示，公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日，云顶新耀宣布，其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国国家药品监督管理局批准。此外，云顶新耀于8月1日宣布战略增持I-Mab公司股权，投资金额达3090万美元，折合约2.426亿港元。此次交易完成后，云顶新耀将合计持有I-Mab约16.1%的股份，成为该公司第一大股东。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1574":"生物医药B类股","BK1161":"生物科技","BK1583":"高瓴概念","01952":"云顶新耀"},"translate_title":"Genting Xinyao rose more than 8% in the afternoon. Naifukang's production expansion has been approved by the State Food and Drug Administration. The company's recent strategy to increase its stake in I-Mab","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"云顶新耀(01952)午后涨超8%，截至发稿，涨8.05%，报67.1港元，成交额4.08亿港元。消息面上，据澎湃报道，近期，有患者在社交平台上发帖称，其使用的布地奈德肠溶胶囊(商品名：耐赋康)出现缺货情况。对于缺货情况，云顶新耀表示，公司已于今年2月向国家药监局提交扩大产能的补充申请。8月4日，云顶新耀宣布，其中国首个且唯一获得完全批准的IgA肾病对因治疗药物耐赋康扩产补充申请已正式获得中国国家药品监督管理局批准。此外，云顶新耀于8月1日宣布战略增持I-Mab公司股权，投资金额达3090万美元，折合约2.426亿港元。此次交易完成后，云顶新耀将合计持有I-Mab约16.1%的股份，成为该公司第一大股东。云顶新耀首席执行官罗永庆表示，此次增加对I-Mab的战略性股权投资，进一步推动了公司在全球范围布局新一代肿瘤免疫治疗管线。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556808239","isCrawlerRequest":true}

云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准 公司近期战略增持I-Mab股权

精彩评论

云顶新耀午后涨超8% 耐赋康扩产已获国家药监局批准公司近期战略增持I-Mab股权